Prolonged Response of Relapsed High Grade Serous Ovarian Carcinoma to the Oral Angiokinase Inhibitor Nintedanib in a Patient with a Germline BRCA1 Mutation

Overview

Journal Gynecol Oncol Case Rep

Publisher Elsevier

Date 2013 Dec 28

PMID 24371652

Authors

Han Hsi Wong

Christine Parkinson

Jonathan A Ledermann

James D Brenton

Michael Merger

Ashley Shaw

Aileen Patterson

Mahmood Shafi

Helena M Earl

Affiliations

Soon will be listed here.

Abstract

► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.

References

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

Tarnowski B, Chudecka-Glaz A, Gorski B, Rzepka-Gorska I . Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients. Breast Cancer Res Treat. 2004; 88(3):287-8. DOI: 10.1007/s10549-004-0779-0. View

Ledermann J, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I . Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011; 29(28):3798-804. DOI: 10.1200/JCO.2010.33.5208. View

Kang H, Kim H, Rih J, Mattson T, Kim K, Cho C . BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem. 2006; 281(19):13047-13056. DOI: 10.1074/jbc.M513033200. View

Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83. DOI: 10.1056/NEJMoa1104390. View

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

Navaraj A, Finnberg N, Dicker D, Yang W, Matthew E, El-Deiry W . Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol Ther. 2009; 8(24):2417-44. PMC: 2975268. DOI: 10.4161/cbt.8.24.10850. View

Aghajanian C, Blank S, Goff B, Judson P, Teneriello M, Husain A . OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 30(17):2039-45. PMC: 3646321. DOI: 10.1200/JCO.2012.42.0505. View

Tagawa T, Morgan R, Yen Y, Mortimer J . Ovarian cancer: opportunity for targeted therapy. J Oncol. 2012; 2012:682480. PMC: 3253450. DOI: 10.1155/2012/682480. View

10.

Kawai H, Li H, Chun P, Avraham S, Avraham H . Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene. 2002; 21(50):7730-9. DOI: 10.1038/sj.onc.1205971. View